This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Exact Sciences Reports Third-Quarter 2012 Financial Results

Stocks in this article: EXAS

Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the quarter ended Sept. 30, 2012.

Exact reported total revenues of $1.0 million for the third quarter of 2012 and the third quarter of 2011. Total revenues for each of the nine-months ended Sept. 30, 2012, and Sept 30, 2011, were $3.1 million.

Exact reported a net loss of ($13.0) million, or ($0.21) a share, for the third quarter of 2012. The company had a net loss of ($7.8) million, or ($0.15) a share, for the same period of 2011. The net loss for the nine-month period ended Sept. 30, 2012, was ($38.4) million, or ($0.66) a share. The company’s net loss for the same period of 2011 was ($18.8) million, or ($0.36) a share.

Operating expenses for the quarter ended Sept. 30, 2012, were $14.0 million, compared to $8.9 million for the third quarter of 2011. Operating expenses for the first nine months of 2012 totaled $41.7 million, compared to $22.0 million during the same period of 2011. Operating expenses for the quarter and nine-month period ended Sept. 30, 2012, increased from the same periods a year ago primarily because of the ongoing clinical trial of the company’s non-invasive colorectal cancer screening test.

Exact ended the third quarter of 2012 with cash, cash equivalents and marketable securities of $118.6 million, compared to $93.4 million at Dec. 31, 2011. The company completed a $57.8-million secondary stock offering in August.

“We are very pleased with the positive data presented recently at the American Association for Cancer Research meeting,” said Kevin T. Conroy, the company’s president and chief executive. “It gives us confidence that the DeeP-C trial will deliver strong results. Both our test and the automation system that will be used to process clinical trial samples performed well in that study.”

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,081.81 +51.60 0.29%
S&P 500 2,090.74 +8.86 0.43%
NASDAQ 4,797.4140 +23.9420 0.50%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs